Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 11/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 3/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.36 |
| ▸ | CCNC | P24863 | 2/20 | 0.36 |
| ▸ | CDK8 | P49336 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29789713 | 1.00 | AR (0.41) | ARCHRM5CHRM1PIK3CDPIK3CA | |
| SCHEMBL23123980 | 0.74 | AR (0.43) | ARPIK3CDPIK3CAPIK3CGPDK2 | |
| SCHEMBL29789758 | 0.74 | AR (0.43) | ARPIK3CDPIK3CAPIK3CGPDK2 | |
| SCHEMBL23123822 | 0.72 | KDM1A (0.41) | AR | |
| SCHEMBL29789643 | 0.72 | KDM1A (0.41) | AR | |
| SCHEMBL16158285 | 0.71 | AR (0.43) | ARPGR | |
| SCHEMBL23123280 | 0.70 | CCNC (0.34) | ARCHRM5CHRM1PIK3CDPIK3CA | |
| SCHEMBL29789803 | 0.70 | CCNC (0.34) | ARCHRM5CHRM1PIK3CDPIK3CA | |
| SCHEMBL5714193 | 0.67 | PDK1 (0.43) | CHRM5CHRM1PDK1PDK2PDK3 | |
| SCHEMBL6649459 | 0.67 | KDM4E (0.50) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
| CN-114901652-A | Substituted saturated and unsaturated N-heterocyclic carboxamides and related compounds for the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021055630-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL- BIOTECH INVESTMENTS, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, CLN6 | AR 2576/4885CHRM5 3785/4885CHRM1 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.